Inflammatory demyelinating diseases of the central nervous system

Galactosemia Drug Pipeline Market Report 2022 Featuring Applied Therapeutics, Jaguar Gene Therapy, & BridgeBio Pharma - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022
Health, Pharmaceutical, FDA, Route of administration, NDA, CNS, Technology, Clinical trial, Route, Inflammatory demyelinating diseases of the central nervous system, Central nervous system, Birth, Lists of diseases, ARI, Jaguar, Degenerative disease, Discovery, Administration, Acquisition, Therapy, GALT, News, Deficiency, Medical device, Oil, Pharmaceutical industry, Glycosylation, Galactosemia

This Galactosemia- Pipeline Insight, 2022 report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Galactosemia pipeline landscape.

Key Points: 
  • This Galactosemia- Pipeline Insight, 2022 report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Galactosemia pipeline landscape.
  • "Galactosemia- Pipeline Insight, 2022" report outlays comprehensive insights of present scenario and growth prospects across the indication.
  • A detailed picture of the Galactosemia pipeline landscape is provided which includes the disease overview and Galactosemia treatment guidelines.
  • Galactosemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

USPTO Issues Patent Covering Use of XPro™ for Treatment of CNS Diseases

Retrieved on: 
Wednesday, June 22, 2022
CNS, Amyotrophic lateral sclerosis, US Foods, Lists of diseases, Security (finance), FDA, Patent, Traffic barrier, CEO, Company, TNF, TRD, USPTO, Degenerative disease, U.S. Securities and Exchange Commission, Cancer, Research, Private Securities Litigation Reform Act, Neurodegeneration, Inflammatory demyelinating diseases of the central nervous system, Disease, Marketing, NASDAQ, Treatment-resistant depression, Central nervous system, Inflammation, Food, OF, BBB, Patient, AD, ALS, GLOBE, Natural killer cell, Pharmaceutical industry

11,365,229 for METHODS OF TREATING NEUROLOGICAL DISEASES, a patent directed to use of Dominant Negative Tumor Necrosis Factor (DN-TNF) variants, such as the Companys XPro, by peripheral administration for crossing the blood-brain barrier (BBB) and treating diseases of the Central Nervous System (CNS).

Key Points: 
  • 11,365,229 for METHODS OF TREATING NEUROLOGICAL DISEASES, a patent directed to use of Dominant Negative Tumor Necrosis Factor (DN-TNF) variants, such as the Companys XPro, by peripheral administration for crossing the blood-brain barrier (BBB) and treating diseases of the Central Nervous System (CNS).
  • The patent is currently set to provide coverage through September 10, 2033, subject to a possible patent term extension if requested by the Company and approved by the USPTO under 35 U.S.C.
  • This patent is the product of real-life data using DN-TNF in both pre-clinical studies and the completed human Phase I study in Alzheimers Disease.
  • Because the drug is self-administered as a once-a-week subcutaneous injection, the patients or their care-givers can administer XPro at home.

Pipeline Therapeutics Reports Positive Phase 1 Clinical Results for PIPE-307, a Neuroregenerative Therapeutic for the Treatment of Multiple Sclerosis

Retrieved on: 
Thursday, March 10, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Safety, Attention, Multiple sclerosis, Volunteering, Single, Senior, MAD, Company, IND, MS, Pharmacokinetics, Even and odd functions, Total survey error, Food, CNS, Neurodegeneration, Investigational New Drug, Inflammatory demyelinating diseases of the central nervous system, Learning, Patient, SAD, US Foods, Nerve, Therapy, PK, Program, CEO, Veps, Adult, Neuro, LinkedIn, Pharmaceutical industry, Pipeline, PIPE-307 for Multiple Sclerosis, Pipeline Therapeutics, PIPE-307 FOR MULTIPLE SCLEROSIS, PIPELINE THERAPEUTICS

Currently, there are no approved medicines that support myelin restoration, which represents a significant unmet medical need in the treatment of MS.

Key Points: 
  • Currently, there are no approved medicines that support myelin restoration, which represents a significant unmet medical need in the treatment of MS.
  • The Phase 1 clinical results reported today comprised multiple dose cohorts of PIPE-307 in a total of 70 healthy volunteer subjects.
  • We believe that PIPE-307, as a first-in-class myelin restoration therapeutic, represents a differentiated and clinically-validated approach for the treatment of MS.
  • These encouraging Phase 1 results give us great confidence to advance PIPE-307 into clinical studies with MS patients as soon as possible.

CHMP Recommends EU Approval of Chugai’s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Retrieved on: 
Monday, April 26, 2021
Biotechnology, Health, Pharmaceutical, Optical, Clinical trials, Autoimmune diseases, Neurological disorders, Clinical medicine, Medicine, Multiple sclerosis, Rare diseases, Central nervous system disorders, Neuromyelitis optica spectrum disorder, Myelitis, NMO, MOG antibody disease, Inflammatory demyelinating diseases of the central nervous system

Patients with NMOSD frequently experience a relapsing disease course with repeated attacks leading to accumulating neurological damage and disability.

Key Points: 
  • Patients with NMOSD frequently experience a relapsing disease course with repeated attacks leading to accumulating neurological damage and disability.
  • Neuromyelitis optica spectrum disorder (NMOSD) Online.
  • Lin J, Li X, Xia J. Th17 cells in neuromyelitis optica spectrum disorder: a review.
  • International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

The Multiple Sclerosis Association of America and Wondros Launch COVID-19 and MS Pathfinder

Retrieved on: 
Tuesday, July 14, 2020
Organ systems, Nervous system, Multiple sclerosis, Autoimmune diseases, Nerve, Lesional demyelinations of the central nervous system, Inflammatory demyelinating diseases of the central nervous system

The COVID-19 and MS Pathfinder tool allows members of the multiple sclerosis (MS) community to search for trusted sources and information related to COVID-19.

Key Points: 
  • The COVID-19 and MS Pathfinder tool allows members of the multiple sclerosis (MS) community to search for trusted sources and information related to COVID-19.
  • The COVID-19 and MS Pathfinder has been designed to easily navigate through various topics including facts about COVID-19 as well as tips to stay safe and healthy.
  • The Multiple Sclerosis Association of America (MSAA) is a national nonprofit organization and leading resource for the entire MS community, improving lives today through vital services and support.
  • Multiple sclerosis (MS) is a disease of the central nervous system (CNS), which consists of the brain, optic nerves, and spinal cord.

Atara Biotherapeutics to Present Initial Efficacy and Additional Safety Results from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019

Retrieved on: 
Monday, September 9, 2019
Multiple sclerosis, Organ systems, Neurological disorders, Medical specialties, Inflammatory demyelinating diseases of the central nervous system, Multiple sclerosis research

Multiple Sclerosis (MS) is a chronic neurological autoimmune disease that affects more than two million people around the world.

Key Points: 
  • Multiple Sclerosis (MS) is a chronic neurological autoimmune disease that affects more than two million people around the world.
  • Progressive MS (PMS) is a severe form of the disease for which there are few therapeutic options.
  • Primary Progressive MS (PPMS) occurs when continuous progressive disease is present at diagnosis and has been reported to occur in approximately 15% of newly diagnosed cases of MS.
  • Atara is advancing an ongoing Phase 1 ATA188 study in patients with progressive MS across clinical sites in the U.S. andAustraliaand plans to initiate a randomized ATA190 study in progressive MS patients.

Mobile App Helps People with Multiple Sclerosis Better Manage Their Disease

Retrieved on: 
Wednesday, June 27, 2018
Multiple sclerosis, Nervous system, Anatomy, Autoimmune diseases, Medicine, Nerve, Inflammatory demyelinating diseases of the central nervous system

CHERRY HILL, N.J., June 27, 2018 /PRNewswire/ -- My MS Manager is the Multiple Sclerosis Association of America's mobile phone app designed to be a convenient and effective tool for members of the MS community to help manage their condition.

Key Points: 
  • CHERRY HILL, N.J., June 27, 2018 /PRNewswire/ -- My MS Manager is the Multiple Sclerosis Association of America's mobile phone app designed to be a convenient and effective tool for members of the MS community to help manage their condition.
  • The app, powered by @Point of Care, is available to download free of charge for both iOS and Android devices.
  • My MS Manager was also recently named one of the Best Multiple Sclerosis Apps of 2018 by Healthline.com.
  • Multiple sclerosis (MS) is a disease of the central nervous system (CNS), which consists of the brain, optic nerves, and spinal cord.

Global Multiple Sclerosis Epidemiology and Patient Flow Analysis 2018

Retrieved on: 
Tuesday, April 17, 2018
Multiple sclerosis, Autoimmune diseases, Immunology, Medicine, Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Inflammatory demyelinating diseases of the central nervous system

The "Global Multiple Sclerosis Epidemiology and Patient Flow Analysis - 2018" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Multiple Sclerosis Epidemiology and Patient Flow Analysis - 2018" report has been added to ResearchAndMarkets.com's offering.
  • The research provides insights into Multiple Sclerosis epidemiology, Multiple Sclerosis diagnosed patients, and Multiple Sclerosis treatment rate for US, Japan, and EU5 countries.
  • The research measures key indicators including prevalence of Multiple Sclerosis derived from epidemiological analysis, patients diagnosed with Multiple Sclerosis, and patients treated with a drug therapy.
  • The research provides estimates and forecasts of Multiple Sclerosis prevalence, Multiple Sclerosis diagnosis rate, and Multiple Sclerosis treatment rate for the period 2017 - 2026.